ALKERMES PLC (ALKS) Stock Price, Forecast & Analysis
USA - NASDAQ:ALKS - IE00B56GVS15 - Common Stock
ALKS Key Statistics, Chart & Performance
The current stock price of ALKS is 32.89 USD. In the past month the price increased by 5.38%. In the past year, price increased by 13.96%.
ALKS Latest News, Press Relases and Analysis
ALKS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.19 | 387.16B | ||
| AMGN | AMGEN INC | 14.64 | 172.38B | ||
| GILD | GILEAD SCIENCES INC | 14.51 | 147.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.59 | 104.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.61 | 69.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 868.04 | 58.03B | ||
| INSM | INSMED INC | N/A | 40.10B | ||
| NTRA | NATERA INC | N/A | 27.39B | ||
| BIIB | BIOGEN INC | 9.29 | 22.80B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.01 | 20.30B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 36.45 | 15.11B |
Related stock screener links
About ALKS
Company Profile
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. The company is headquartered in Dublin, Dublin and currently employs 1,800 full-time employees. The firm has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. The company focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. The company has a manufacturing facility in Wilmington, Ohio.
Company Info
ALKERMES PLC
Connaught House, 1 Burlington Road, Dublin 4
DUBLIN DUBLIN DUBLIN 4 IE
CEO: Richard F. Pops
Employees: 1800
Phone: 35317728000
ALKERMES PLC / ALKS FAQ
What does ALKS do?
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. The company is headquartered in Dublin, Dublin and currently employs 1,800 full-time employees. The firm has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. The company focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. The company has a manufacturing facility in Wilmington, Ohio.
What is the current price of ALKS stock?
The current stock price of ALKS is 32.89 USD. The price increased by 3.82% in the last trading session.
What is the dividend status of ALKERMES PLC?
ALKS does not pay a dividend.
What is the ChartMill technical and fundamental rating of ALKS stock?
ALKS has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
On which exchange is ALKS stock listed?
ALKS stock is listed on the Nasdaq exchange.
What do analysts say about ALKERMES PLC (ALKS) stock?
22 analysts have analysed ALKS and the average price target is 44.61 USD. This implies a price increase of 35.63% is expected in the next year compared to the current price of 32.89.
What is the ownership structure of ALKERMES PLC (ALKS)?
You can find the ownership structure of ALKERMES PLC (ALKS) on the Ownership tab.
ALKS Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ALKS. When comparing the yearly performance of all stocks, ALKS is one of the better performing stocks in the market, outperforming 83.24% of all stocks.
ALKS Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to ALKS. ALKS scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
ALKS Financial Highlights
Over the last trailing twelve months ALKS reported a non-GAAP Earnings per Share(EPS) of 2.48. The EPS increased by 19.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 22.27% | ||
| ROA | 14.54% | ||
| ROE | 19.55% | ||
| Debt/Equity | 0 |
ALKS Forecast & Estimates
22 analysts have analysed ALKS and the average price target is 44.61 USD. This implies a price increase of 35.63% is expected in the next year compared to the current price of 32.89.
For the next year, analysts expect an EPS growth of -48.02% and a revenue growth -2.6% for ALKS